Europe Hemoglobinopathies Market Size, Share & Industry Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Distribution Channel, By Therapy (Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors), By Country and Growth Forecast, 2

Europe Hemoglobinopathies Market Size, Share & Industry Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease), By Distribution Channel, By Therapy (Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors), By Country and Growth Forecast, 2022 - 2028

The Europe Hemoglobinopathies Market would witness market growth of 5.2% CAGR during the forecast period (2022-2028).

HbS, HbD, HbE, and HbG are more frequently seen as beta-globin variants. A mutation in one beta globin component generates a blend of regular and variant hemoglobin, which creates a heterozygote state, commonly known as a trait or carrier status. Mutations in both beta globin components are because of diseases based on a homozygous or heterozygous expression. Mutations are homozygous with a synthesis of HbS in the case of sickle cell anemia (HbSS).

No matter whether it is an alpha globin or beta globin variant, the seriousness of the disease can be inconsequential or fatal. Therefore, it is necessary to identify it through newborn screening. In 2006, the Recommended Uniform Screening Panel (RUSP) added Hemoglobinopathies, specially HbSS, HbSC disease, and Hbs/beta-thalassemia, to their list.

Jointly the Maternal and Child Health Bureau of the Health Resources and Services Administration (HRSA) of the United States and the American College of Medical Genetics (ACMG) concluded that these illnesses are clinically severe and can be easily identified during newborn screening. Depending upon the severity of the disease connected with sickle cell disorder, they were added. Extreme pain, anemia, and vaso occlusive crisis, which in the end affects multiple organ systems and eventually worsens with time, are some of its symptoms.

The Pediatric and Adult hemoglobinopathy Outpatients Units of the University Hospital of Essen conducted a study and summarized the outcomes of hemoglobinopathies which was before the introduction of the general newborn screening for SCD in Germany. A total of 339 patients were diagnosed by molecular analysis, out of which 182 were minors (50.5% males) and 157 adults (75.8% females). Due to the migration and the late diagnosis of second/third-generation migrants, hemoglobinopathy is posing serious health problems in Germany.

The Germany market dominated the Europe Hemoglobinopathies Market by Country in 2021; thereby, achieving a market value of $399.3 Million by 2028. The UK market is exhibiting a CAGR of 4.3% during (2022 - 2028). Additionally, The France market would experience a CAGR of 5.9% during (2022 - 2028).

Based on Type, the market is segmented into Thalassemia, Sickle Cell Disease and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacy, Hospital Pharmacy and Online Providers. Based on Therapy, the market is segmented into Monoclonal Antibody Medication, Hydroxyurea, ACE Inhibitors and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Sanofi S.A., Danaher Corporation, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Merck & Co., Inc., Bristol Myers Squibb Company, Alnylam Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., Biogen, Inc. and Canthera Discovery Ltd.

Scope of the Study

Market Segments covered in the Report:

By Type

• Thalassemia
• Sickle Cell Disease
• Others

By Distribution Channel

• Drug Stores & Retail Pharmacy
• Hospital Pharmacy
• Online Providers

By Therapy

• Monoclonal Antibody Medication
• Hydroxyurea
• ACE Inhibitors
• Others

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Companies Profiled

• Abbott Laboratories
• Sanofi S.A.
• Danaher Corporation
• Pfizer, Inc. (Global Blood Therapeutics, Inc.)
• Merck & Co., Inc.
• Bristol Myers Squibb Company
• Alnylam Pharmaceuticals, Inc.
• Emmaus Life Sciences, Inc.
• Biogen, Inc.
• Canthera Discovery Ltd.

Unique Offerings from KBV Research

• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free